Cost considerations in the management of atrial fibrillation – impact of dronedarone

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaykin, Yaariv, Shamiss, Yana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304332/
https://www.ncbi.nlm.nih.gov/pubmed/22427725
http://dx.doi.org/10.2147/CEOR.S16675
Descripción
Sumario:Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramount importance. This review will discuss AF treatment strategies and economics, focusing on the impact of dronedarone, a novel antiarrhythmic agent.

Ejemplares similares